Roland W. Burli PhD

Roland studied chemistry and did his PhD at the ETH (Zürich) on the synthesis and characterization of complex carbohydrate mimetics. He then did postdoctoral work at Caltech (USA) where he investigated sequence-specific DNA binding ligands. Prior to joining AstraZeneca, he worked in several small and large biotech companies (GeneSoft, Amgen, BioFocus) in the USA and the UK. He worked on many projects ranging from early hit identification to late-stage preclinical projects and candidate selection in several therapeutic areas. Over the past ~8 years, he has been focusing on new therapies for neurodegenerative diseases and neurological disorders.